‘Far from clear’ new Alzheimer’s drugs will make a difference at a population level, say researchers
Writing in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the team from Cambridge Public Health argue that substantial challenges including the risk-benefit ratio, limited eligibility and high cost of roll-out will limit any benefits of these treatments.Alzheimer’s disease is often quoted as causing 70% of the 55 million…